Back to search results

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Small Cell Lung Cancer · SCLC · Extensive Stage Small Cell Lung Cancer · Limited Stage Small-Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

    Contact: Study coordinator (Margaret Uhrich, RN) · muhrich@iu.edu
    Contact: Principal Investigator (Misty Shields, MD, PhD)

  • University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

    Contact: Study coordinator (David Akinbo) · david-akinbo@uiowa.edu
    Contact: Principal Investigator (Muhammad Furqan, MD)

  • Karmanos Cancer Center (Wayne State University), Detroit, Michigan, United States

    Contact: Study coordinator (Hirva Mamdani, MD) · mamdanih@karmanos.org · 313-576-8711
    Contact: Principal Investigator (Hirva Mamdani, MD)

  • University of Virginia Health System, Charlottesville, Virginia, United States

    Contact: Study coordinator (Lacey Garrett) · lb5tu@uvahealth.org
    Contact: Principal Investigator (Ryan Gentzler, MD)
Study leads

  • Hirva Mamdani, MD

    Principal Investigator

    Wayne State University

View source on ClinicalTrials.gov(opens in a new tab)